BAP1-defective cancers: Targeting with BET inhibitors shows high specificityCAR T-cell therapy: Effective in preclinical models, promising for checkpoint-resistant melanomasHuman endogenous retroviruses (HERVs): Potential new targets for low-mutational cancers. Here, DNER is linked to cancer.